Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2000

View Archived Issues

Southern Research Institute to evaluate CR-1013 for drug delivery potential

Novel class of antibiotic peptides reported

Abgenix and Immunex join forces for development of anticancer antibodies

Company Profile: MelTec

Bristol-Myers Squibb seeks FDA approval to begin systemic CA4P trials

Xoma highlights recent developments

Protherics' angiotensin vaccine heads for phase II

Anxiolytic NGD-91-3 advances through the clinical pipeline

Modex Therapeutiques announces progress in Q3

Postischemic NS-7 reduces histological and neurological brain damage in rats

Neuroprotective profile of SUN-N4057 further defined in small animals

Phase I/IIa results for UK-279276 presented at World Stroke Congress; phase IIb trial begins

Positive preliminary response rate reported for RSR-13 in NSCLC

Prous Science Puts Postgraduate Training Online

(S)-(-)-AR-A008055, a new gabamimetic agent related to clomethiazole, exerts neuroprotective effect

Oral diltiazem carbomer may have beneficial effects in esophageal spasm

Axonyx begins study of tolserine for memory enhancement

Fungally produced anthelmintic agent discovered at Meiji Seika

Active components of traditional Indonesian asthma medicine identified

SMP-2: new polyene antifungal antibiotic identified by Ajinomoto

Bisanthraquinone antibacterial agents reported by Yamanouchi

Potential new agents for asthma selectively inhibit human PDE4

Novo Nordisk/Boehringer Ingelheim collaboration discovers new series of H3 receptor antagonists

CRC describes new prodrugs for cancer ADEPT or GDEPT

Dual 5-HT1A ligands/5-HT transporter inhibitors under study at AHP for depression

Selective NK3 receptor antagonists patented by Neurogen R&D team

Favorable preclinical results for huN901-DM1/BB-10901 support rapid advance to clinic

GEM-231 can be safely used with taxanes in advanced cancer patients according to phase I data